Plus therapeutics receives fda fast track designation for 186rnl targeted radiotherapeutic for leptomeningeal metastases

Austin, texas, nov. 09, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the u.s. food and drug administration (fda) has granted the company fast track designation for rhenium-186 nanoliposome (186rnl) for the treatment of leptomeningeal metastases (lm), a rare complication in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord, affecting nearly 5% of people living with cancer. the company recently announced clearance of its investigational new drug (ind) application from the fda, and expects to initiate patient accrual in the respect-lm phase 1 dose escalation clinical trial of 186rnl in the fourth quarter of 2021.
pstv Ratings Summary
pstv Quant Ranking